

Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

October 6, 2025

Alfresa Holdings Corporation
Kidswell Bio Corporation
Chiome Bioscience Inc.
Mycenax Biotech Inc.

Agreement in Principle to Establish a Joint Venture Alliance under the Ministry of Health, Labour and Welfare's Subsidy Program for the Development of Domestic Manufacturing Facility for Biosimilars

Alfresa Holdings Corporation (head office: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter "Alfresa Holdings"); Kidswell Bio Corporation (head office: Chuo-ku, Tokyo; President & CEO: Shinya Kurebayashi; hereinafter "Kidswell"); Chiome Bioscience Inc. (head office: Shibuya-ku, Tokyo; President & CEO: Masamichi Koike; hereinafter "Chiome"), and Mycenax Biotech Inc. (head office: Hsinchu, Taiwan; CEO and President : Pei-Jiun Chen; hereinafter "Mycenax") have reached a basic agreement to establish a joint venture for the manufacturing of drug substance and formulations of biosimilars*¹. This initiative is intended to advance the project adopted under the Ministry of Health, Labour and Welfare (hereinafter "the MHLW")'s "Subsidy Program for the Development of Domestic Manufacturing Facilities for Biosimilars" (hereinafter "the Subsidy Program"), with the manufacturing facility to be constructed on the premises of Alfresa Fine Chemical Corporation (head office: Akita City, Akita; President & CEO: Masaki Amano; hereinafter "Alfresa Fine Chemical"), a subsidiary of Alfresa Holdings.

Alfresa Holdings, Kidswell, and Chiome jointly applied for the public offering under the MHLW's Subsidy Program to build a stable domestic supply system for biosimilars and were selected on May 21, 2025. Mycenax is also participating in this Subsidy Program as an important stakeholder*²

Based on this basic agreement, Alfresa Holdings, Kidswell, Chiome, and Mycenax will establish a joint venture to advance the development of a domestic manufacturing facility for biopharmaceuticals, including biosimilars (hereinafter "biosimilars, etc."), on the premises of Alfresa Fine Chemical with the Subsidy Program of the MHLW, and will promote a CDMO*³ business for biosimilars, etc. Furthermore, by combining the distribution capabilities of the Alfresa Group, the four companies will work to build a total value chain for biosimilars, thereby contributing to improving domestic supply

capabilities and ensuring a stable domestic supply system for biosimilars, enabling the export of domestically manufactured biosimilar drug substances and formulations, as well as fostering the development of skilled professionals in the field of biopharmaceutical research and manufacturing, ultimately supporting the advancement of Japan's biopharmaceutical industry.

Details such as the name and location of the joint venture will be determined through further discussions.

Note 1: An equivalent product of the equivalent quality of a reference (original) biologic that has already been approved and sold in Japan that is sold by a different pharmaceutical manufacturer following the patent expiration and reexamination period of the original biologic

Note 2: "Notice Regarding Selection for Subsidies Under the Ministry of Health, Labour and Welfare Support Program for the Establishment of Domestic Manufacturing Facilities for Biosimilars and Start of a Collaborative Development Project for a Manufacturing Facility "

https://ssl4.eir-parts.net/doc/2784/ir_material17/251107/00.pdf

Note 3: CDMO (Contract Development and Manufacturing Organization): An organization that undertakes the process from the development of manufacturing process through clinical trial materials to commercial production of pharmaceuticals.

■ About Alfresa Holdings

Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, "we create and deliver a fresh life for all," the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. The company will continue to evolve and expand its total supply chain services to provide integrated services across the Group, from the introduction, development, and manufacture of pharmaceuticals and other products through to their distribution, sale, and post-marketing surveillance, as well as last-mile operations.

For more information: <https://www.alfresa.com/eng/>

■ About Kidswell

Kidswell upholds a corporate philosophy of "biotech striving for value creation—for a comprehensive healthcare system for children, families, and society." Under this philosophy, it promotes its biosimilars business, a stable earnings base that has already launched four biosimilar

pharmaceuticals, and a cell therapy (regenerative medicine) business, which has one potential product in the clinical development stage and is expected to become a foundation for considerable growth in the future. The company engages in R&D activities every day, striving to provide patients suffering from illness with innovative medicines and treatments and thereby help realize a society in which people can live brighter and happier lives.

For more information: <https://www.kidswellbio.com/en/>

■ About Chiome

Chiome is a biotech company dedicated to the discovery and development of antibody drug candidates to treat diseases with high unmet medical needs with its proprietary technologies, such as the ADLib® system and Tribody®, its polyspecific antibody production technology. In addition to its drug discovery and development business, which handles in-house drug discovery, and its drug discovery support business, which provides high-quality technical services to pharmaceutical manufacturers and other organizations, the company promotes collaboration with pharmaceutical manufacturers and start-ups as a form of integrated drug discovery (IDD), aimed at contributing toward biosimilar-related business and promoting movement in the Japan's drug discovery ecosystem.

For more information: <https://www.chiome.co.jp/?id=en>

■ About Mycenax

Mycenax is a pioneer in the biopharmaceutical CDMO industry in Taiwan, with a value chain that covers a full range of processes, from cell line construction, production, analytical methods, and formulation development to commercial production and aseptic filling. Out of its development and manufacturing base in Taiwan, the company has integrated the upstream and downstream areas of the biopharmaceutical field and provides CDMO services to customers around the world.

For more information: <https://www.mycenax.com/about.php?id=28&lang=en>

For Project-Related Inquiries

Alfresa Holdings Corporation
Corporate Communication Department
Email: ir@alfresa.com

Kidswell Bio Corporation
Corporate Planning Department
Email: info@kidswellbio.com

Chiome Bioscience Inc.
IR Representative
Email: ir@chiome.co.jp